CiteFacts · FDA Drug Shortages · FDA source
FDA shortage status: Valproate Sodium Injection
FDA source answer
FDA currently lists this ingredient in shortage.
FDA source statuses: Current. First FDA posting: 2020-12-30. Latest FDA row update: 2026-09-18.
FDA lists 2 package records, with companies: Fresenius Kabi USA, LLC, Hikma Pharmaceuticals USA Inc., Hikma Pharmaceuticals USA, Inc.. Package NDCs: 0143-9785-10, 63323-494-05.
FDA shortage reason: Not stated in the grouped FDA source rows.
This is nationwide FDA status, not local pharmacy inventory. CiteFacts does not provide medical, treatment, substitution, or dosing advice.
FDA package and manufacturer records
| Company | Package NDC | Presentation | FDA availability field | FDA update |
|---|---|---|---|---|
| Fresenius Kabi USA, LLC | 63323-494-05 | Valproate Sodium, Injection, 100 mg/1 mL (NDC 63323-494-05) | Available | 2026-09-15 |
| Hikma Pharmaceuticals USA, Inc. | 0143-9785-10 | Valproate Sodium, Injection, 500 mg/5 mL (NDC 0143-9785-10) | Available | 2026-09-18 |
Source facts
Grouped generic ingredient: Valproate Sodium Injection · 2 package records
Therapeutic categories: Neurology
Dosage forms: Injection
Routes: INTRAVENOUS
Open FDA source data · JSON · Markdown
FDA is authoritative. Source retrieved 2026-10-06T18:55:41+00:00. Derived grouping is documented in this record's derivations.